Send to

Choose Destination
Mucosal Immunol. 2019 Jul;12(4):1013-1024. doi: 10.1038/s41385-019-0167-z. Epub 2019 May 19.

Topical application of human-derived Ig isotypes for the control of acute respiratory infection evaluated in a human CD89-expressing mouse model.

Author information

CSL Limited, Bio21 Institute, 30 Flemington Rd, Parkville, VIC, 3010, Australia.
CSL Limited, Bio21 Institute, 30 Flemington Rd, Parkville, VIC, 3010, Australia.
Department of Microbiology and Immunology The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.
CSL Behring AG, Wankdorfstrasse 10, 3010, Bern, Switzerland.
Center for Transgenic Models, Mattenstrasse 22, 4002, Basel, Switzerland.
CSL Behring AG, Wankdorfstrasse 10, 3010, Bern, Switzerland.


Recurrent and persistent airway infections remain prevalent in patients with primary immunodeficiency (PID), despite restoration of serum immunoglobulin levels by intravenous or subcutaneous plasma-derived IgG. We investigated the effectiveness of different human Ig isotype preparations to protect mice against influenza when delivered directly to the respiratory mucosa. Four polyvalent Ig preparations from pooled plasma were compared: IgG, monomeric IgA (mIgA), polymeric IgA-containing IgM (IgAM) and IgAM associated with the secretory component (SIgAM). To evaluate these preparations, a transgenic mouse expressing human FcαRI/CD89 within the myeloid lineage was created. CD89 was expressed on all myeloid cells in the lung and blood except eosinophils, reflecting human CD89 expression. Intranasal administration of IgA-containing preparations was less effective than IgG in reducing pulmonary viral titres after infection of mice with A/California/7/09 (Cal7) or the antigenically distant A/Puerto Rico/8/34 (PR8) viruses. However, IgA reduced weight loss and inflammatory mediator expression. Both IgG and IgA protected mice from a lethal dose of PR8 virus and for mIgA, this effect was partially CD89 dependent. Our data support the beneficial effect of topically applied Ig purified from pooled human plasma for controlling circulating and non-circulating influenza virus infections. This may be important for reducing morbidity in PID patients.


Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center